Hualan Biological Engineering's forecast growth is lower than the wider market, coupled with a weak earnings outlook. This suggests that the share price is at risk of declining, potentially leading to a lower P/E.
The market's past overconfidence in the company is evident in the steeper share price decline compared to the EPS slippage. Despite recent losses, the stock's 0.6% annual return over five years suggests short-term issues. Investors should monitor the company's fundamentals closely.
$Hualan Biological Engineering, Inc. (002007.SZ)$ Does this mean, this company will very soon have another share listed? For example there is Pfizer, then they “created” BioNTech. Hualan Biological Engineering's Vaccine Unit Gets Exchange's Nod For IPO Aug 26 (Reuters) - Hualan Biological Engineering Inc <002007.SZ>::SAYS ITS VACCINE UNIT GETS NOD FROM SHENZHEN STOCK EXCHANGE FOR INITIAL PUBLIC SHARE OFFERING. 4 days ago
Hualan Biological Engineering, Inc. Stock Forum
Does this mean, this company will very soon have another share listed?
For example there is Pfizer, then they “created” BioNTech.
Hualan Biological Engineering's Vaccine Unit Gets Exchange's Nod For IPO
Aug 26 (Reuters) - Hualan Biological Engineering Inc <002007.SZ>::SAYS ITS VACCINE UNIT GETS NOD FROM SHENZHEN STOCK EXCHANGE FOR INITIAL PUBLIC SHARE OFFERING.
4 days ago
No comment yet